Nanomedicine News

RSS

Simvastatin-Loaded Nanoparticles Target Inflamed Immune Cells Within High-Risk Arterial Plaques

A research team showed that a nanotherapeutic medicine can halt the growth of artery plaque cells resulting in the fast reduction of the inflammation that may cause a heart attack, according to a study led by researchers from Icahn School of Medicine at Mount Sinai and published April 3 in Science Advances.

6 Apr 2015

Simple $1 Nanoparticle-Enabled Dynamic Light Scattering Assay Better than Standard Test for Prostate Cancer

A test that costs less than a $1 and yields results in minutes has been shown in newly published studies to be more sensitive and more exact than the current standard test for early-stage prostate cancer.

6 Apr 2015

BIND and Pfizer Extend Global Collaboration for Accurins Targeted Therapeutics

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced an extension of the terms of its global collaboration with Pfizer Inc. to create Accurins that optimize the therapeutic potential of two molecularly targeted oncology drugs in Pfizer’s pipeline.

6 Apr 2015

Nanofibre Gel Drug Delivery Systems May Help Avoid Side Effects of Painkillers

A Chemistry undergraduate at the University of York has helped to develop a new drug release gel, which may help avoid some of the side effects of painkillers such as ibuprofen and naproxen.

3 Apr 2015

Small Gold Nanoparticles Conjugated with miR-182 Sequences Cross Blood-Brain/Blood-Tumor Barrier

Northwestern Medicine scientists have identified a small RNA molecule called miR-182 that can suppress cancer-causing genes in mice with glioblastoma mulitforme (GBM), a deadly and incurable type of brain tumor.

3 Apr 2015

University of Queensland Antibody for Human Hendra Virus Clinical Trial

An antibody manufactured at The University of Queensland will be used in world-first human Hendra virus clinical trials starting this month.

3 Apr 2015

Kala Reports Top-Line Results from KPI-121 Nanoparticle Loteprednol Etabonate MPP Phase 3 Trial in Cataract Surgery

Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, today announced positive top-line results from a Phase 3 clinical trial of KPI-121, its nanoparticle loteprednol etabonate MPP product candidate, for the treatment of inflammation and pain in patients who had undergone cataract surgery.

2 Apr 2015

Nanoparticle Carrier Delivers Antibacterial Agent into Dental Plaque

Therapeutic agents intended to reduce dental plaque and prevent tooth decay are often removed by saliva and the act of swallowing before they can take effect. But a team of researchers has developed a way to keep the drugs from being washed away.

2 Apr 2015

New Method for Embedding Scaffolding of Patterned Nanofibers within 3D Hydrogel Structures

Damage to neural tissue is typically permanent and causes lasting disability in patients, but a new approach has recently been discovered that holds incredible potential to reconstruct neural tissue at high resolution in three dimensions.

2 Apr 2015

Liposomes, Magnetic Nanoparticles and Photosensitizers Combined to Fight Cancer

By combining, in a liposome, magnetic nanoparticles and photosensitizers that are simultaneously and remotely activated by external physical stimuli (a magnetic field and light), scientists at the Laboratoire Matière et Systèmes Complexes (CNRS/Université Paris Diderot) and the Laboratoire Physicochimie des Electrolytes et Nanosystèmes Interfaciaux (CNRS/UPMC), obtained total tumor regression in mice.

2 Apr 2015